EP1390385A4 - Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme - Google Patents
Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femmeInfo
- Publication number
- EP1390385A4 EP1390385A4 EP02752028A EP02752028A EP1390385A4 EP 1390385 A4 EP1390385 A4 EP 1390385A4 EP 02752028 A EP02752028 A EP 02752028A EP 02752028 A EP02752028 A EP 02752028A EP 1390385 A4 EP1390385 A4 EP 1390385A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- conditions
- nucleic acid
- acid based
- female reproductive
- based modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06021209A EP1767632A3 (fr) | 2001-05-29 | 2002-05-29 | Méthode d'administration locale d'oligonucléotides synthétiques double-brins dirigés contre un récepteur du VEGF |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US870161 | 1997-06-06 | ||
US87016101A | 2001-05-29 | 2001-05-29 | |
US33446101P | 2001-11-30 | 2001-11-30 | |
US334461P | 2001-11-30 | ||
US138674 | 2002-05-03 | ||
US10/138,674 US7034009B2 (en) | 1995-10-26 | 2002-05-03 | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
PCT/US2002/017674 WO2002096927A2 (fr) | 2001-05-29 | 2002-05-29 | Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06021209A Division EP1767632A3 (fr) | 2001-05-29 | 2002-05-29 | Méthode d'administration locale d'oligonucléotides synthétiques double-brins dirigés contre un récepteur du VEGF |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1390385A2 EP1390385A2 (fr) | 2004-02-25 |
EP1390385A4 true EP1390385A4 (fr) | 2004-11-24 |
Family
ID=27385212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02752028A Withdrawn EP1390385A4 (fr) | 2001-05-29 | 2002-05-29 | Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1390385A4 (fr) |
JP (2) | JP2005500025A (fr) |
AU (1) | AU2002344237B8 (fr) |
CA (1) | CA2448320A1 (fr) |
GB (1) | GB0404461D0 (fr) |
WO (1) | WO2002096927A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030216335A1 (en) * | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
WO2002081628A2 (fr) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique |
US7833992B2 (en) * | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US7491805B2 (en) * | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050014172A1 (en) | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
FR2832154B1 (fr) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
AU2006203062B2 (en) * | 2002-02-20 | 2009-03-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
MXPA04010282A (es) | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo. |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
WO2006006948A2 (fr) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree |
EP2314691A3 (fr) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | SIRNA fonctionnel et hyperfonctionnel |
JP2006523226A (ja) * | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | T細胞調節方法 |
AU2004220459B2 (en) * | 2003-03-12 | 2010-08-05 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2004082626A2 (fr) * | 2003-03-18 | 2004-09-30 | Ethicon, Inc. | Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase |
AU2005212433B2 (en) | 2003-05-23 | 2010-12-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA) |
WO2005007853A2 (fr) * | 2003-06-06 | 2005-01-27 | Senesco Technologies, Inc. | Inhibition d'eif-5a specifique de l'apoptose ('eif-5a1') au moyen d'oligonucleotides antisens et de petits arn interferents utilises comme agents therapeutiques anti-inflammatoires |
AU2004269150C1 (en) * | 2003-08-28 | 2010-11-18 | Novartis Ag | Interfering RNA duplex having blunt-ends and 3'-modifications |
US8258105B2 (en) | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
EP1711510A4 (fr) * | 2004-02-05 | 2008-11-26 | Intradigm Corp | Therapeutique par des agents rnai appliquee dans le traitement de maladies oculaires resultant d'une neovascularisation |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
CA2572223C (fr) * | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Inhibiteurs d'angiogenese |
AU2005299672A1 (en) * | 2004-10-22 | 2006-05-04 | Benitec, Inc. | Therapeutic RNAi agents for treating psoriasis |
US20090010907A1 (en) * | 2004-12-14 | 2009-01-08 | National Institute Of Immunology | Dnazymes for Inhibition of Japanese Encephalitis Virus Replication |
BRPI0610499A2 (pt) | 2005-04-12 | 2010-06-22 | Intradigm Corp | moléculas de ácido nucléico , composições e usos das referidas moléculas |
US7893244B2 (en) | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
US8093259B2 (en) * | 2006-05-25 | 2012-01-10 | Novartis Ag | 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma |
US7872118B2 (en) | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
CA2745832A1 (fr) | 2008-12-04 | 2010-06-10 | Opko Ophthalmics, Llc | Compositions et procedes pour l'inhibition selective d'isoformes pro-angiogeniques de vegf |
US20120128673A1 (en) | 2009-05-20 | 2012-05-24 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
SG2014008171A (en) | 2009-06-22 | 2014-04-28 | Ampio Pharmaceuticals Inc | Method for treatment of diseases |
WO2011031600A1 (fr) | 2009-09-10 | 2011-03-17 | Schering Corporation | Utilisation d'antagonistes de l'il-33 à des fins de traitement des maladies fibrotiques |
EP2513308B1 (fr) | 2009-12-17 | 2017-01-18 | Merck Sharp & Dohme Corp. | Modulation de pilr pour le traitement de troubles immunitaires |
WO2012015775A2 (fr) | 2010-07-28 | 2012-02-02 | Dharmacon, Inc. | Siarn ciblant la vegfa et méthodes de traitement in vivo |
EP3372684B1 (fr) | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Agents d'arni à un seul brin contenant un espaceur interne d'acide non nucléique |
CA2810928A1 (fr) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Analogues nucleotidiques substitues |
EP3766975A1 (fr) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
WO2013053076A1 (fr) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions et procédés pour le traitement de l'insuffisance cardiaque |
CA2860234A1 (fr) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Analogues de nucleotide phosphorothioate substitue |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
WO2013142157A1 (fr) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Combinaisons pharmaceutiques comprenant un analogue thionucléotidique |
US9351979B2 (en) | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
JP6568052B2 (ja) * | 2013-05-22 | 2019-09-04 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. | 心不全を治療するためのニューレグリンの徐放 |
CN103627709A (zh) * | 2013-12-06 | 2014-03-12 | 孙仑泉 | 抑制血管内皮生长因子受体基因表达的脱氧核酶 |
AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997015662A2 (fr) * | 1995-10-26 | 1997-05-01 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif de traitement de maladies ou troubles lies aux niveaux du recepteur du facteur de croissance endotheliale vasculaire |
WO2003070910A2 (fr) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Inhibition induite par interference d'arn du facteur de croissance endothelial vasculaire et expression genetique du recepteur de facteur de croissance endothelial vasculaire au moyen d'acides nucleiques interferents courts (sina) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001510808A (ja) * | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
-
2002
- 2002-05-29 JP JP2003500106A patent/JP2005500025A/ja active Pending
- 2002-05-29 CA CA002448320A patent/CA2448320A1/fr not_active Abandoned
- 2002-05-29 AU AU2002344237A patent/AU2002344237B8/en not_active Ceased
- 2002-05-29 EP EP02752028A patent/EP1390385A4/fr not_active Withdrawn
- 2002-05-29 WO PCT/US2002/017674 patent/WO2002096927A2/fr not_active Application Discontinuation
-
2004
- 2004-02-27 GB GBGB0404461.6A patent/GB0404461D0/en active Pending
-
2008
- 2008-06-06 JP JP2008149684A patent/JP2009000106A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997015662A2 (fr) * | 1995-10-26 | 1997-05-01 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif de traitement de maladies ou troubles lies aux niveaux du recepteur du facteur de croissance endotheliale vasculaire |
WO2003070910A2 (fr) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Inhibition induite par interference d'arn du facteur de croissance endothelial vasculaire et expression genetique du recepteur de facteur de croissance endothelial vasculaire au moyen d'acides nucleiques interferents courts (sina) |
Non-Patent Citations (4)
Title |
---|
ELBASHIR S.M. ET AL: "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", EMBO JOURNAL, vol. 20, no. 23, 3 December 2001 (2001-12-03), OXFORD UNIVERSITY PRESS, SURREY, GB, pages 6877 - 6888, XP002225998 * |
ELBASHIR SAYDA M ET AL: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 498, XP002206451, ISSN: 0028-0836 * |
MCLAREN J: "Vascular endothelial growth factor and endometriotic angiogenesis", HUMAN REPRODUCTION UPDATE, vol. 6, no. 1, January 2000 (2000-01-01), pages 45 - 55, XP002298154, ISSN: 1355-4786 * |
PARRISH S ET AL: "Functional anatomy of a dsRNA trigger: Differential requirement for the two trigger strands in RNA interference", MOLECULAR CELL, vol. 6, no. 5, November 2000 (2000-11-01), pages 1077 - 1087, XP002226298, ISSN: 1097-2765 * |
Also Published As
Publication number | Publication date |
---|---|
JP2005500025A (ja) | 2005-01-06 |
GB0404461D0 (en) | 2004-03-31 |
JP2009000106A (ja) | 2009-01-08 |
AU2002344237B8 (en) | 2008-11-06 |
WO2002096927A3 (fr) | 2003-02-20 |
AU2002344237B2 (en) | 2008-10-23 |
EP1390385A2 (fr) | 2004-02-25 |
CA2448320A1 (fr) | 2002-12-05 |
WO2002096927A2 (fr) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1390385A4 (fr) | Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme | |
AU2002365157A8 (en) | Methods and systems of nucleic acid sequencing | |
EP1427746A4 (fr) | Systemes d'expression de proteines et d'acides nucleiques | |
GB0415646D0 (en) | Waveguide and method of manufacture | |
EP1578954A4 (fr) | Acides nucleiques 5'cpg et leurs methodes d'utilisation | |
AU7878301A (en) | Method of amplifying nucleic acid | |
AU2001281028A1 (en) | Dilute acid/metal salt hydrolysis of lignocellulosics | |
HK1062836A1 (en) | Nucleic acid vaccines for prevention of flavivirusinfection | |
HK1067666A1 (en) | Nucleic acid triplex and quadruplex formation | |
AU2002353095A8 (en) | Streptavidin expressed gene fusions and methods of use thereof | |
HUP0303517A3 (en) | Nucleotide sequence mediating male fertility and method of using same | |
EP1383865A4 (fr) | Procede de production de tyrosine, d'acide cinnamique et d'acide para-hydroxycinnamique | |
IL157176A0 (en) | Purification of 2-nitro-4-methylsulphonylbenzoic acid | |
IL156804A0 (en) | Modulation of gsk-3beta activity and its different uses | |
AU2002306850A1 (en) | Methods and reagents for decreasing clinical reaction to allergy | |
AU2002246926A1 (en) | 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof | |
EP1490381A4 (fr) | Gene humain essentiel pour la fertilite | |
AU2002366435A8 (en) | Nucleic acid amplification | |
AUPR721101A0 (en) | Nucleic acid and polypeptide linked to breast cancer | |
EP1463523A4 (fr) | Proteine et acide nucleique du gene 1 induit par l'acide retinoique de type gpcr | |
AU2002333558A1 (en) | Methods of selecting 5'-capped nucleic acid molecules | |
IL147734A0 (en) | Thermistor and method of manufacture | |
AU2002254126A1 (en) | Nucleic acids for transforming fish cells and methods for their use | |
AU2002365759A1 (en) | Identification of rearrangements in nucleic acid molecules | |
AU2002310840A1 (en) | Nucleic acid sequences of hyperplasies and tumors of the thyroid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031125 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GORDON, GILAD Inventor name: SANDBERG, JENNIFER Inventor name: STINCHCOMB, DAN Inventor name: PAVCO, PAMELA Inventor name: MCSWIGGEN, JAMES Inventor name: ESCOBEDO, JAIME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041008 |
|
17Q | First examination report despatched |
Effective date: 20050207 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20061102 |